NOVO NORDISK Aktie

 

The pharmaceutical giant still has plenty of work to do to recover from recent woes....

Earlier this year, Novo Nordisk A/S pulled off the best obesity-drug launch ever with its Wegovy pill. Now it's focused on building on more than 600,000 prescriptions as Eli Lilly & Co. threatens to siphon patients away with a new pill of its own....

Eli Lilly & Co.'s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year....

The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market....

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market....

Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care....

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset. The following five companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify ... These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target The post These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target appeared first on 24/7 Wall St.....

Die britische Gesundheitsbehörde empfiehlt den Einsatz von Wegovy zur Reduktion schwerer Herz- und Kreislaufrisiken. So reagiert die Novo Nordisk-Aktie....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Die Novo Nordisk-Aktie dümpelt seit über einem Monat knapp über der Marke von 30 €. Könnte diese Nachricht dem dänischen Pharmakonzern neuen Schwung geben? Wegovy zukünftig im Abo Novo Nordisk bekommt den Preisdruck bei Abnehmmitteln in den USA voll zu spüren. Nachdem die Dänen bereits Ende Februar den Listenpreis ihres Adipositas-Medikaments Wegovy deutlich gesenkt haben, […] The post Novo Nordisk-Aktie: Ist das ein kluger Schachzug? first appeared on sharedeals.de....

The new recommendation will significantly expand access to Wegovy on the England's NHS....

– Conference Call Today at 4:30 p.m. ETSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 million non-cash charge associated with the mark-to-market adjustment on the embedded derivatives related to our 2029 Notes and Term Loan. Excluding the non-cash charge associated with the embedded derivatives, non-GAAP adjusted net income for the three months and year ...

Novo Nordisk startet eine neue Strategie gegen Eli Lilly – mit hohen Einsparungen für Patienten....

Die Euphorie im Zuge der Meldung einer Partnerschaft mit Novo Nordisk vom 9. März katapultierte die Hims & Hers-Aktie mit einem großen Up-Gap gen Norden. Vom Tief des 6. März bis zum Hochpunkt der Bewegung zum 11. März schossen die Notierungen um rund +81% empor. Die Ernüchterung folgte postwendend und all die zuvor erzielte Performance […] The post Hims & Hers-Aktie: Pure Ernüchterung nach +81% first appeared on sharedeals.de....

Von Dominic Chopping DOW JONES--Novo Nordisk bietet sein Adipositas-Medikament Wegovy in den USA ab sofort im Abonnement an. Mit einem "niedrigeren, vorhersehbaren Monatspreis" sollen neue Kunden gewonnen werden. Der dänische Pharmakonzern ......

Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk...

Novo Nordisk India has cut prices of its blockbuster weight-loss and diabetes medications, as an onset of cheaper generic drugs raises competition for the Danish drugmaker in the world's third most overweight country....

The Wegovy® injectable and pill are now available at even lower cash pay prices on Ro NEW YORK, March 31, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that patients can save up to $1,200/year on the Wegovy® pen or $600/year on the Wegovy® pill......

Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform...

New subscription-based option helps eligible self-pay patients start and stay on Wegovy® with predictable pricing Available March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and other telehealth providers coming online soon Program builds on Novo Nordisk's......